1 |
Song J, Yoon YM, Jung HJ, Hong SH, Park H, and Kim JQ (2000) Plasminogen activator inhibitor-1 4G/5G promoter polymorphism and coagulation factor VII arg353 Gln polymorphism in Korean patients with coronary artery disease. J Korean Med Sci 15: 146-152
DOI
|
2 |
Teger-Nilsson AC, Larsson T, Hjemdahl P, and Olsson G (1991) Fibrinogen and plasminogen activator inhibitor-1 levels in hypertension and coronary heart disease. Circulation 84 Suppl VI: VI-72-VI-77
|
3 |
Tishkoff SA, Ruano G, Kidd JR, and Kidd KK (1996) Distribution and frequency of a polymorphic Alu insertion at the plasminogen activator locus in humans. Hum Genet 97: 759-764
DOI
|
4 |
van den Eijnden-Schrauwen Y, Lakenberg N, Emeis JJ, and de Knijff P (1995) Alu-repeat polymorphism in the tissue-type plasminogen activator (tPA) gene does not affect basal endothelial tPA synthesis. Thromb Haemost 74: 1202
|
5 |
van der Bom JG, de Knijff P, Haverkate F, Bots ML, Meijer P, de Jong PTVM, Hofman A, Kluft C, and Grobbee DE (1997) Tissue plasminogen activator and risk of myocardial infarction. Circulation 95: 2623-2627
DOI
|
6 |
Wang B, Zhou X, Dang A, Liu G, and He R (2002) Alu-repeat polymorphism in the gene coding for tissue-plasminogen activator and the risk of hypertension in a Chinese Han population. Hypertens Res 25: 949-953
DOI
ScienceOn
|
7 |
Wiman B and Hamsten A (1990) The fibrinolytic enzyme system and its role in the etiology of thromboembolic disease. Semin. Thromb Hemost 16: 207-216
DOI
|
8 |
Yang-Feng TL, Opdenakker G, Volckaert G, and Francke U (1986) Human tissue-type plasminogen activator gene located near chromosomal breakpoint in myeloproliferative disorder. Am J Hum Genet 39: 79-87
|
9 |
Mune T, Rogerson FM, Nikkila H, Agarwal AK, and White PC (1995) Human hypertension caused by mutations in the kidney isozyme of 11 beta-hydroxysteroid dehydrogenase. Nat Genet 10: 394-399
DOI
ScienceOn
|
10 |
Novick GE, Novick CC, Yunis J, Yunis E, de Mayolo PA, Scheer WD, Deninger PL, Stoneking M, York DS, Batzer MA, and Herrera RJ (1998) Polymorphic Alu insertions and the Asian origin of native American populations. Hum Biol 70: 23-39
|
11 |
Ny T, Sawdey M, Lawrence D, Millan JL, and Loskutoff DJ (1986) Cloning and sequencing of a cDNA coding for the human beta-migrating endothelial-cell-type plasminogen activator inhibitor. Proc Natl Acad Sci USA 83: 6776-6780
DOI
ScienceOn
|
12 |
Orita M, Iwahana H, Kanazawa H, Hayashi K, and Sekiya T (1989a) Detection of polymorphisms of human DNA by gel electrophoresis as single-strand conformation polymorphisms. Proc Natl Acad Sci USA 86: 2766-2770
DOI
ScienceOn
|
13 |
Orita M, Suzuki T, Sekiya T, and Hayashi K (1989b) Rapid and sensitive detection of point mutations and genetic polymorphisms using polymerase chain reaction. Genomics 5: 874-879
DOI
|
14 |
Shimkets RA, Warnock DG, Bositis CM, Nelson-Williams C, Hansson JH, Schambelan M, Gill JR Jr, Ulick S, Milora RV, and Findling JW (1994) Liddle's syndrome: heritable human hypertension caused by mutations in the beta subunit of the epithelial sodium channel. Cell 79: 407-414
DOI
ScienceOn
|
15 |
Mansfield MW, Stickland MH, and Grant PJ (1995) Environmental and genetic factors in relation to elevated circulating levels of plasminogen activator inhibitor-1 in Caucasian patients with non-insulin-dependent diabetes mellitus. Thromb Haemost 74: 842-847
|
16 |
Luft FC (1999) Bad genes, good people, association, linkage, longevity and the prevention of cardiovascular disease. Clin Exp Pharmacol Physiol 26: 576-579
DOI
|
17 |
McCormack LJ, Nagi DK, Stickland MH, Mansfield MW, Mohamed-Ali V, Yudkin JS, Knowler WC, and Grant PJ (1996) Promoter (4G/5G) plasminogen activator inhibitor-1 genotype in Pima Indians: relationship to plasminogen activator inhibitor-1 levels and features of the insulin resistance syndrome. Diabetologia 39: 1512-1518
DOI
ScienceOn
|
18 |
Molnar-Gabor E, Endreffy E, and Rozsasi A (2000) HLA-DRB1, -DQA1, and DQB1 genotypes in patients with nasal polyposis. Laryngoscope 110: 422-425
DOI
ScienceOn
|
19 |
Loskutoff DJ (1991) Regulation of PAI-1 gene expression. Fibrinolysis 5: 197-206
DOI
ScienceOn
|
20 |
Klinger KW, Winqvist R, Riccio A, Andreasen PA, Sartorio R, Nielsen LS, Stuart N, Stanislovitis P, Watkins P, and Douglas R (1987) Plasminogen activator inhibitor type 1 gene is located at region q21.3-q22 of chromosome 7 and genetically linked with cystic fibrosis. Proc Natl Acad Sci USA 84: 8548-8552
DOI
ScienceOn
|
21 |
Kooistra T, Bosma PJ, Tors HAM, van den Berg AP, Meyer P, and Princen HMG (1989) Plasminogen activator inhibitor 1: biosynthesis and mRNA level are increased by insulin in cultured human hepatocyte. Thromb Haemost 62: 723-728
|
22 |
Lander ES and Schork NJ (1994) Genetic dissection of complex traits. Science 265: 2037-2048
|
23 |
Landin K, Tengborn L, and Smith U (1990) Elevated fibrinogen and plasminogen activator inhibitor-1 (PAI-1) in hypertension are related to metabolic risk factors for cardiovascular disease. J Int Med 227: 273-278
DOI
ScienceOn
|
24 |
Henry M, Chomiki N, Scarabin PY, Alessi MC, Peiretti F, Arveiler D, Ferrieres J, Evans A, Amouyel P, Poirier O, Cambien F, and Juhan-Vague (1997) Five frequent polymorphisms of the PAI-1 gene: lack of association between genotypes, PAI-1 activity, and triglyceride levels in a healthy population. Artheroscler Thromb Vasc Biol 17: 851-858
DOI
|
25 |
Lifton RP, Dluhy RG, Powers M, Rich GM, Cook S, Ulick S, and Lalouel J-M, A. (1992) Chimaeric 11 synthase gene causes glucocorticoid-remediable aldosteronism and human hypertension. Nature 355: 262-265
DOI
ScienceOn
|
26 |
Fridewald WT, Levy Rl, and Friedrickson DS (1972) Estimation of the concentration of low-density lipoprotein cholesterol in plasma without the use of the preparative ultracentrifuge. Clin Chem 18: 499-502
|
27 |
Grenett HE, Khan N, Jiang W, and Booyse F (2000) Identification of the Hind III polymorphic site in the PAI-1 gene: analysis of the PAI-1 Hind III polymorphism by PCR. Genet Test 4: 65-68
DOI
ScienceOn
|
28 |
Jeng JR, Harn HJ, Yueh KC, Jeng CY, and Shieh SM (1998) Plasminogen activator inhibitor-1 and angiotensin I converting enzyme gene polymorphism in patients with hypertension. Am J Hypertens 11: 235-239
DOI
ScienceOn
|
29 |
Jeng JR, Sheu WHH, Jeng CY, Huang SH, and Shieh SM (1996) Impaired fibrinolysis and insulin resistance in patients with hypertension. Am J Hypertens 9: 484-490
DOI
ScienceOn
|
30 |
Kang BY, Kim KT, Eo HS, Lee KH, Hong SS, Shin JH, and Lee CC (2000) Association between genetic variation of the insulin receptor gene and essential hypertension in the Korean population. Korean J Biol Sci 4: 87-90
DOI
|
31 |
Benza RL, Grenett HE, Li XL, Reeder VC, Brown SL, Go RCP, Hanson KA, Perry GJ, Holman WL, McGiffin DC, Kirk KA, and Booyse FM (1998) Gene polymorphisms for PAI-1 are associated with the angiographic extent of coronary artery disease. Thromb Thrombol 5: 143-150
DOI
ScienceOn
|
32 |
Kim HS, Hwang KY, Chung IK, Park SH, Lee MH, Kim SJ, and Hong SY (2003) Tissue plasminogen activator and plasminogen activator inhibitor type 1 gene polymorphism in patients with gastric ulcer complicated with bleeding. J Korean Med Sci 18: 58-64
DOI
|
33 |
Kim JQ, Song JH, Park YB, and Hong SS (1998) Molecular basis of coronary heart disease. J Korean Med Sci 13: 1-15
|
34 |
Andreasen PA, Georg B, Lund LR, Riccio A, and Stacey SN (1990) Plasminogen activator inhibitors: hormonally regulated serpins. Mol Cell Endocrinol 68: 1-19
DOI
ScienceOn
|
35 |
Collen D (1980) On the regulation and control of fibrinolysis. Thromb Haemost 43: 77-89
|
36 |
Dawson SJ, Hamsten A, Wiman B, Henney A, and Humphries S (1991) Genetic variation at the plasminogen activator inhibitor-1 locus is associated with altered levels of plasminogen activator inhibitor-1 activity. Arterioscler Thromb 11: 183-190
DOI
|
37 |
Falk G, Almqvist A, Nordenhem A, Svensson H, and Wiman B (1995) Allele specific PCR for detection of a sequence polymorphism in the promoter region of the plasminogen activator inhibitor-1 (PAI-1) gene. Fibrinolysis 9: 170-174
DOI
ScienceOn
|